Schrodinger (SDGR) is offering 10m shares at $14-16 for a $1B market cap. We expect the shares to perform well in part given that they are backed by two notable investors, David Shaw and Bill Gates, and they have a strong position in enabling new drug discovery and the development of new materials. It also helps that they have multiple revenue streams to leverage their substantial platform investment.
Their core value proposition is simple enough - we can accelerate your discovery process and provide a higher probability of success at the same time. Here's their vision . . .